Lower pretreatment serum testosterone level predicts poor prognosis in the patients with metastatic hormone-sensitive prostate cancer undergoing androgen deprivation therapy.
Takahiro YoshidaTaketo KawaiKanade HagiwaraKazuki YanagidaMichio NodaYuumi TokuraItsuki YoshimuraTomoyuki KanekoTohru NakagawaPublished in: Japanese journal of clinical oncology (2024)
Lower baseline serum testosterone levels predict poor prognosis in patients with metastatic hormone-sensitive prostate cancer.